N/A N=68 Restorative Exercise for Strength Training and Operational Resilience (RESTORE) for Chronic or Recurrent Low Back Pain
Lower Back Pain
Primary: Pain Scores — 4.32; 4.68; 3.97; 2.60 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=44 A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation
Pulmonary Disease, Chronic Obstructive
Primary: Change in Messenger Ribonucleic Acid (mRNA) Transcriptome in Induced Sputum After 12, 28 and 84 Days of Treatment (Selected Probe Sets With Fold Change >1.5 or <-1.5 and…
Phase 2 N=60 Study to Evaluate a HIV Drug for the Treatment of HIV Infection
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Change in Plasma Log10 HIV-1 Ribonucleic Acid (RNA) Levels From Baseline to Day 11 — -0.138; -0.567; -0.889; -1.279 Log10 copies per milliliter (c/mL)
Phase 3 N=1,098 Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia
Schizophrenia
Primary: Change From Randomization to Week 10 in Positive and Negative Syndrome Scale (PANSS) Total Score — -10.01; -8.22; -9.90 units on a scale — p=0.9196
N/A N=5,381 Isotonic Solutions and Major Adverse Renal Events Trial in the Medical Intensive Care Unit
Critical Illness · Acute Kidney Injury
Primary: Major Adverse Kidney Event Within 30 Days — 659; 615 Participants — p=<0.05
N/A N=26 CE Mark Study for the Harpoon Medical Device
Mitral Valve Regurgitation · Mitral Valve Prolapse · Mitral Valve Insufficiency
Primary: Subject's Procedural Success During the First 30 Days — 23 Participants
Phase 2 N=24 An 8-Week Refractory Chronic Cough Study (MK-7264-021)
Refractory Chronic Cough
Primary: Change From Baseline in Awake Cough Frequency After 8 Weeks of Treatment. — -7.5; -16.9; -18.5; 0.3 Coughs/hour
N/A N=80 3D Versus 2D Laparoscopic Ovarian Cystectomy
Surgical Procedure, Unspecified
Primary: The Duration of Laparoscopic Ovarian Cystectomy — 51.6; 47.6 minutes — p=0.198
Phase 3 N=12,019 A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Heart Failure · Respiratory Insufficiency · Stroke Acute
Primary: Time From Randomization to First Occurrence of Composite of All Symptomatic Venous Thromboembolism (VTE) and VTE Related Death Adjudicated by Clinical Event Committee…
N/A N=26 CE Mark Study for the Harpoon Medical Device in Poland
Mitral Valve Regurgitation · Mitral Valve Prolapse · Mitral Valve Insufficiency
Primary: Subject's Procedural Success During the First 30 Days — 24 Participants
N/A N=56 The Effects of Emotional Exposure on State Anxiety
Generalized Anxiety Disorder
Primary: STAI-Y1 Score Assessed at Baseline, Post-Condition and Post-Exposure — 33.48; 33.53; 27.43; 29.78 score on a scale — p=>.05
Phase 4 N=359 Clinical and Economic Implications of Genetic Testing for Warfarin Management
Blood Coagulation Disorders
Primary: Inpatient Length of Stay — 6.8; 7.2 days
Phase 4 N=240 Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations
Influenza
Primary: Number of Participants (Group 1: Aged 6 to <36 Months) Reporting Solicited Injection Site Reactions and Systemic Reactions — 15; 3; 4; 2 Participants
Phase 2 N=308 A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery
VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery
Primary: Number of Participants With Treatment-emergent Bleeding Events (Clinical Events Committee [CEC]- Adjudicated) — 2; 0; 5; 1 Participants
Phase 1 N=26 A Study to Compare the Amount of Meloxicam in the Blood When it is Taken as Capsules or as Tablets
Healthy
Primary: Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-t) — 27870.56; 30051.25 Nanogram…